N esiritide is recombinant B-type natriuretic peptide (BNP) 1-4 approved for use in patients with acute heart failure, because of its ability to reduce pulmonary-capillary wedge pressure and improve dyspnea. 3, 5 Yet after approval, it was suggested that nesiritide might cause renal toxicity and increase mortality. Specifically, in a meta-analysis of 5 randomized studies with 1269 acute heart failure patients compared with placebo, intravenous nesiritide increased the rate of worsening renal function by 50%, although confidence intervals around this estimate were wide. 6,7 These concerns led to a marked decrease in the use of nesiritide. 8
decompensated heart failure (ADHF) patients. Overall, compared with placebo, nesiritide did not improve (or worsen) clinical outcomes and nesiritide did not increase the risk of worsening renal function (predefined as >25% decrease in estimated glomerular filtration rate). 9 Our study was a retrospective analysis of ASCEND-HF, in which we examined the detailed effects of nesiritide on renal function, clinical predictors of changes in creatinine, and the relationship between changes in renal function and outcomes.
Methods
ASCEND-HF was a randomized, double blind, placebo-controlled trial of nesiritide in addition to standard of care. 10 The trial was conducted from May 2007 through August 2010 at 398 international centers. Patients were included if they were hospitalized for heart failure occurring within 24 hours before they received their first intravenous treatment for heart failure, or if they had received a diagnosis of ADHF <48 hours after hospitalization for another cause, and underwent randomization within 24 hours after intravenous treatment. Patients were excluded if they had a high risk of hypotension (systolic pressure <100 mm Hg or 110 mm Hg with the use of intravenous nitroglycerin), other contraindications for vasodilators, persistent uncontrolled hypertension, normal levels of BNP or N-terminal proBNP (NT-proBNP), chronic or intermittent renal support therapy (ie, hemodialysis, ultrafiltration, or peritoneal dialysis), or clinically significant anaemia. 10 Eligible patients were randomly assigned in a 1:1 ratio to receive nesiritide or placebo, in addition to standard therapy. After a recommended (but optional) intravenous bolus of nesiritide, at a dose of 2 μg per kilogram, nesiritide was administered as a continuous infusion of 0.010 μg per kilogram per minute for 24 hours or more, for up to 7 days.
The ASCEND-HF study was approved by each participating center's ethics committee or institutional review board, and all participants provided written informed consent (ClinicalTrials.gov #: NCT00475852).
Patients for Analyses
A total of 7141 patients underwent randomization; of these, 7007 (98%) received the study drug and were included in the modified intention-to-treat analysis. The study groups were well-balanced and similar to the intention-to-treat group. 9 Our retrospective analysis of ASCEND-HF focuses on the 5702 patients who had both baseline and inpatient peak creatinine measurement available for review ( Table I in 
Worsening Renal Function
Worsening renal function was defined as an increase of serum creatinine >0.3 g/dL (26.5 μmol/L) and ≥25% change. 11, 12 Creatinine was measured at baseline and at discharge.
End Points
The primary end point of interest in this study is the composite of rehospitalization for heart failure and death from any cause within 30 days postevent. The other end point of interest was the separate outcome of rehospitalization for heart failure or death from any cause within 30 days. The following criteria were required for hospitalization events to be classified as attributable to heart failure: typical clinical manifestations of worsening heart failure and the addition of (or increase in) treatment specifically for worsening heart failure with an intravenous pharmacological agent, or mechanical or surgical intervention or ultrafiltration, hemofiltration, or dialysis specifically for the management of persistent or worsening heart failure.
Statistical Analyses
Change in creatinine was defined as the change from baseline to peak during hospitalization ( Table 1 , which displays 2 groups, those changes ≤0.3 mg/dL and those >0.3 mg/dL). 13, 14 Presenting factors, baseline medications, and medical history information is reported as counts and frequencies for discrete factors and either the mean with standard deviation or 50 th , 25 th , and 75 th percentiles for continuous. A Wilcoxon rank-sum test was performed for continuous factors, and a χ 2 test was performed for binary measurements.
Cox proportional hazards regression modeling was generated to assess the association between prespecified baseline factors and change in creatinine (from randomization to discharge). To verify modeling assumptions, plots were generated to view the residuals of each independent predictor. Outliers of creatinine measurements ≥10 mg/dL were excluded. The blood urea nitrogen (BUN), BNP, and NT-proBNP were modeled using log transformations. A test for normality was evaluated. The stepwise variable selection procedure was applied using a P value of 0.05 for to enter and stay in the model. Interactions between treatment and baseline factors were reviewed.
Analyses on the prognostic value of serum creatinine were separated into 2 cohorts. The first and most valuable cohort consisted of all patients having baseline values of serum creatinine as well as one or more other serum creatinine values. Of all serum creatinine values during hospitalization, the highest value was taken as peak serum creatinine value. Change in creatinine values was calculated as peak value minus baseline value. The second smaller cohort consisted of patients having baseline and discharge values of creatinine, ignoring other serum creatinine values during hospitalization.
Baseline, discharge, peak, and change from baseline to each creatinine measurement were modeled univariably as predictors of 30-day mortality and 30-day mortality or rehospitalization for heart failure. These same measurements were also added to previously generated multivariable models for 30-day mortality and 30-day mortality or rehospitalization for heart failure. The 30-day mortality model includes age, sodium, systolic blood pressure, dyspnea, BNP, and NT-proBNP. The combination end point of 30-day mortality and rehospitalization includes age, cerebrovascular disease, chronic respiratory disease, depression, hospitalization within the past year, sodium, qualifying jugular venous pressure episode, systolic blood pressure, weight, BNP, and NT-proBNP. Each creatinine term was added individually to assess the measurement's importance after adjusting for these baseline characteristics. The baseline, peak, and discharge measurements were modeled using the log transformation. The log of creatinine is also analyzed using each measure in a time-dependent covariate analysis unadjusted and adjusted for the prespecified baseline confounders. This time-dependent analysis provided updated assessments of creatinine measures over time. The time-dependent variable is initially set to the baseline measure. As follow-up time matches the date that a new creatinine measurement is observed, the time-dependent variable is changed to the updated value. Creatinine and BUN measurements are displayed at different time points in Figure 1 . The cumulative distribution of creatinine measurements by treatment at the end of treatment and discharge are displayed in Figure 2 . Kaplan-Meier plots were generated to display the relationship of worsening renal failure and 30-day mortality. SAS version 9.2 (SAS Institute, Cary, NC) was used for all analyses.
Results
Baseline characteristics (as presented in Table 1 ) of the 5702 patients who were included in the present study did not clinically differ from the 1439 patients who were excluded because of missing creatinine data (data not shown). Patients who were excluded were 66.3±14.6 years old (versus 65.3±14.0, P=0.002 for the included patients), 33% were female (versus 34%, P=0.437), and had similar systolic and diastolic blood pressures (122 versus 123 mm Hg [P=0.198] and 73 versus 75 mm Hg [P=0.001], respectively). Although excluded patients had modestly higher baseline weight (80 versus 77 kg, P<0.001) they had a similar drop in weight during hospitalization (−2.2 versus −2.3 kg, P=0.829). Excluded patients 
Change in Renal Function
Median creatinine concentration increased from 1.2 (1.0-1.6) mg/dL at baseline to a maximum of 1.4 (1.1-1.8) mg/dL during hospitalization. Median BUN concentration increased from 25 mmol/L at baseline to a maximum of 33 (23-50) mmol/L during hospitalization. The change from randomization to hospital discharge in both serum creatinine and BUN was similar in nesiritide-and placebo-treated patients (P=0.20 and P=0.41, respectively) as shown in Figure 1 and supported by the cumulative distribution curves shown in Figure 2 .
As shown in Table 1 , patients were split by those with a change in creatinine >0.3 mg/dL between baseline and peak. Patients with worsening renal function were older; more often female; and more often had diabetes mellitus, higher left ventricular ejection fraction, higher baseline systolic blood pressure, more cardiovascular comorbidities, a higher weight at baseline, and a larger decrease in weight during hospitalization.
Worsening renal function at any time from randomization through discharge occurred in 13.5% of the patients, and the frequency was similar in the nesiritide and placebo groups (14.1% and 12.8%, respectively; odds ratio [OR] with nesiritide, 1.12; 95% confidence interval [CI], 0.95-1.32; P=0. 19 ), regardless of the degree of baseline renal insufficiency (OR, 1.01; 95% CI, 0.79-1.28; P=0.955 in patients with baseline estimated glomerular filtration rate <60 mL/min/1.73 m 2 , and OR, 1.24; 95% CI, 0.98-1.57; P=0.076 in patients with baseline estimated glomerular filtration rate ≥60 mL/min/1.73 m 2 ).
Using a multivariable stepwise model, we defined characteristics that were related to changes in creatinine ( Table 2) . All prespecified factors included in the stepwise model are identified in Table 1 with a " † " symbol. In summary, a lower baseline BUN (log β = −0.091, P<0.0001), a higher systolic blood pressure (β = 0.002, P<0.0001), a lower diastolic blood pressure (β = −0.002, P<0.0001), a lower baseline potassium (β = −0.040, P<0.0001), and previous weight gain (β = 0.039, P<0.0001) were all significantly related to an increase in serum creatinine. Treatment with nesiritide did not have a significant relation to a change in creatinine (β = 0.001, P=0.89). In the subset of patients who had creatinine values measured at baseline and discharge, we found that both creatinine measures had strong associations with 30-day mortality (multivariable, P<0.001). Change in creatinine was also predictive of 30-day mortality (P<0.001; Table 3 ). In the set of patients with measures of both baseline and peak creatinine values, creatinines remained significant for 30-day mortality after adjusting for potential confounders, as did the change from baseline to peak (P=0.003, P=0.003, and P=0.01, respectively). The multivariable statistical significance of the evaluation of all creatinine values, updated across the hospitalization, was similar to that of the updated changes from baseline across time (P<0.001). Table 4 shows creatinine at discharge, peak, and across all values. All had strong associations with the combined end point of 30-day mortality or rehospitalization, even after adjusting for baseline covariates (P<0.001).
Discussion
In the present renal retrospective analysis of the ASCEND-HF trial, we found that nesiritide did not have any effect on changes in creatinine during hospitalization in patients with ADHF. By any point in time during hospitalization, renal function as measured by creatinine was associated with 30-day death and 30-day death or rehospitalization including baseline, discharge, peak, change, or the most recent measure.
Worsening Renal Function
Renal dysfunction is prevalent in patients with both chronic and acute heart failure, and may influence patients' treatments and outcomes. 15, 16 Approximately 20% to 40% of patients with acute heart failure have an increase in creatinine, which is generally defined as worsening renal function. 15 We also found that the prevalence of diabetes mellitus was higher in patients with worsening renal function, which confirms previous studies. 17, 18 In our study, we found that baseline renal function was mildly impaired and further deteriorated during hospitalization. Predictors of a decline in renal function (measured using creatinine on a continuous scale) included higher systolic and lower diastolic blood pressure, lower potassium levels, more previous weight gain, and lower BUN levels. Similar predictors were found in previous studies. 12, [19] [20] [21] 
Nesiritide
In a meta-analysis of 5 randomized studies that included 1269 ADHF patients, the frequency of worsening renal function was found to be 50% more prevalent in the nesiritide group. 6 Therefore, the neutral effects of nesiritide on renal function in the present study are markedly different from the meta-analysis. There are several potential explanations for this difference. First, in 3 of the 5 studies, detailed data could not be obtained because they have not been published. 22 In the remaining 2 studies, nesiritide was not compared with placebo (as in ASCEND-HF), but was compared with either dobutamine 23 or nitroglycerin 3 ; we cannot exclude the possibility that these agents may have had a positive effect on renal function. Second, ASCEND-HF excluded patients with high risk of hypotension (systolic pressure <100 mm Hg or 110 mm Hg with the use of intravenous nitroglycerin), whereas the Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) and Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Nesiritide Therapy (PRECEDENT) trials had less strict exclusion criteria for hypotension (90 mm Hg and 85 mm Hg, respectively). Finally, in the meta-analysis, the confidence intervals around the estimate were wide, suggesting that larger studies were needed. Also, publication of meta-analysis data from another study suggested that nesiritide might even improve renal function. 23 Given the large sample size, ASCEND-HF had definitive power to demonstrate a meaningful difference in renal function between placebo and nesiritide, yet no difference was found. 9 The present retrospective analysis of ASCEND-HF presents a more detailed report on the associations between nesiritide and other clinical predictors on changes in creatinine and BUN during hospitalization, as well as the drug's association with clinical outcomes. We demonstrated that there was not a significant relationship between nesiritide and change in renal function when corrected for clinical characteristics and other laboratory measurements. 
Renal Effects of Nesiritide 963
Because hypotension is related to worsening renal function in ADHF, 24 there was some concern that patients with hypotension had a higher rate of renal impairment compared with those without hypotension. We found this concern to be true in the overall group, as well as within each treatment group. Importantly, the overall relative risk of increased serum creatinine was the same within both treatment groups. So despite there being some correlation between hypotension and renal dysfunction, there was no evidence of a stronger correlation when using nesiritide.
Outcomes
The conclusions on prognostic value of serum creatinine were drawn from the cohort of patients having baseline values, as well as ≥1 other creatinine values during hospitalization at any time. Importantly, we have also reported the results that were generated when ignoring creatinine values not being measured at discharge. Although the significance of the prognostic values may be attributable to ascertainment bias, we believe that in the setting of a randomized, clinical trial with standardized measurement times of creatinine, it is more likely that the difference in P values is attributable to a different sample size of the 2 cohorts. We suggest measuring creatinine values more than once during hospitalization, for it is important to understand that the time of ascertainment of creatinine values can yield differences in the association with outcomes.
Both serum creatinine at baseline and serum creatinine at discharge had a strong association with both 30-day mortality and with the combined end point of 30-day mortality or rehospitalization. Because change in renal function is a function of the baseline and discharge measures, it is not surprising that it, too, was also associated with short-term outcomes. Likewise, when examining the most recent measure of renal function, it is strongly associated with clinical outcomes.
A large number of studies reported an association between in-hospital worsening renal function and short-term outcomes in patients with ADHF. 11, 12, [25] [26] [27] [28] [29] [30] [31] [32] However, others did not show such an association, 33 perhaps because of patients having a good diuretic response, developing a transient rise in creatinine, but having a good clinical outcome. In contrast, patients with a poor diuretic response and developing worsening renal function have a poor clinical outcome.
Differences in outcomes of studies relating worsening renal function in acute decompensated heart failure to outcome might also be caused by a measurement bias. Most studies do not measure creatinine routinely, so in those that did, there was probably a reason, which perhaps means that these patients were more likely to have worsening of symptoms or nonresponse to diuretics [34] [35] [36] related to clinical outcomes. This theory of measurement bias is supported by a recent study composed of 599 patients who had their serum creatinine levels routinely measured. 32 The authors of this study concluded that worsening renal function is not an independent predictor of outcomes in patients with ADHF. Interestingly, they found that worsening renal function was prognostic in patients with persistent signs of congestion, suggesting a differential effect of worsening renal function. This may explain, at least to a degree, the strong significance noted in the models which used all creatinine measures updated over time compared with the model with discharge or peak only.
Limitations
Our study had several limitations. First, our study was a retrospective analysis. Second, our study has a possible selection bias inherent in clinical trial populations. For example, our population largely consisted of North American patients, possibly limiting the generalizability of our findings. Third, treatment bias could have occurred because concurrent medication could have been altered as a result of changes in creatinine. Finally, 1439 patients did not have serial creatinine values during the inpatient stay, which could have potentially biased the finding that worsening renal function did not predict patient outcomes. For example, patients who lacked serial creatinine values could have developed worsening renal function in-hospital and died before their serial creatinine was measured. Nevertheless, because of the design of ASCEND-HF, this study is more likely to have missing data because of less specific reasons, whereas other studies are more likely to have missing values because patients had no clinical suspicion to have worsening renal function or worse clinical outcomes.
Conclusions
In the present renal retrospective analysis of ASCEND-HF patients who were hospitalized with ADHF, nesiritide did not affect renal function. In addition, baseline, discharge, and change in renal dysfunction were associated with higher 30-day mortality and rehospitalization for heart failure.
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